

# **Role of Stem cells in the treatment of Sensorineural hearing loss**

*Essay*

Submitted for Partial Fulfillment of Master Degree  
In Otolaryngology and Head&Neck surgery

*By*

**Michel George Iskander**

*Under Supervision of*

**Prof. Dr./ Mohamed Magdy Samir**

Professor Of otolaryngology and Head & Neck Surgery  
Faculty of Medicine – Ain Shams University

**Dr./ Mohamed Amir Hassan**

Assistant Professor of Otolaryngology and Head & Neck Surgery  
Faculty of Medicine – Ain Shams University

Faculty of Medicine  
Ain-Shams University  
2012

*Dr. HASSAN*  
*Hassan*

*Nadia Hossainy*

## **Introduction**

Sensorineural hearing loss (SNHL) is a type of hearing loss caused by irreversible loss of inner hair cells which may lead to loss of spiral ganglion neurons (SGNs) or is caused by damage to the inner ear nerves (vestibulocochlear nerve) or central processing centers of the brain (*Haynes, 2009*). SNHL can be present at birth (congenital), or may develop in children or adults later, sudden or slowly progressive in life (acquired). SNHL includes two types Sensory hearing loss and Neural hearing loss (*Ceylan, 2007*).

SNHL is the most common sensory disorder in humans and it accounts for about 90% of all hearing loss and it is found in 23% of population older than 65 years of age (*Margolis, 2008*). In Egypt, the prevalence of SNHL in the Egyptian elderly (>65 years) is reported to be 44.3% (*Abdel-Hamid et al., 2007*).

As the hair cells (HCs) or the sensory neurons donot have the potential to regenerate in the mammalian cochlea. So,the treatment of the SNHL constitutes one of the greatest challenges in the treatment of inner ear disease (*Raphael, 2002*).

Treatment of SNHL has many methods includes the cochlear implantation, the auditory brainstem implant (ABI)

and cellular replacement. The cochlear implant directly stimulate the auditory nerve, bypassing damaged portions of the inner ear but postimplantation rehabilitation ,the high costs of the operation and prosthesis have a heavy influence in their accessibility (*Spahr et al., 2004*).

Auditory brainstem implant (ABI) is similar to cochlear implant but it stimulates the cochlear nucleus (CN).This requires an electrode implanted directly into the brainstem, making this device more risky and still not widely used (*Moore et al., 2009*).

Cellular replacement is a promising therapeutic strategy as cell substitution therapy by replacement or restoration of damaged HCs and/or SGNs has the potential to have a highly significant impact on human health over the next few decades (*Rivolta et al., 2010*).

Stem cells (SC) are excellent candidates for biological implantation as they have the potential to proliferate and differentiate, both required features for a regenerative strategy option (*Naito et al., 2004*).

There are four main SC sources for regeneration of ciliary cells which are: Stem cells isolated from the internal ear itself, embryonic stem cells, neural stem cells and mesenchyme stem cells of bone marrow. The Stem cells which are isolated from the internal ear itself as the utricular epithelium of adult

mammals contain support cells with progenitor properties. Many researches were done on these cells in mammals (adult rat, chicken embryo), it was found that these cells when implanted in other organs (developing ears, muscles and liver of chicken embryo) were capable of proliferation, were totally incorporated suggesting multipotent features of such stem cells (*Li et al., 2003*).

Embryonic Stem Cells which are originated from a cell group from inside the blastocyst, when implanted in deaf laboratory animals result in floating of cells in the perilymph and its adherence in the cochlear cytoarchitecture (*Coleman et al., 2006*).

Neural SC are able to differentiate in the main kinds of neural cells: neurons, astrocyte and oligodendrocyte, when implanted in the internal ear of adult laboratory animals it survived for at least 4 weeks after the implantation and migrated to functionally important regions: Corti organ, spiral ganglion and auditory nerve (*Hu et al., 2005*)

Mesenchyme SC of bone marrow is able to differentiate into several cell kinds (osteoblasts, chondrocyte, myoblasts, adipocyte and neurons) and are easily obtained. After implanting autologous cells of bone marrow in internal ear of rats carrying induced deafness, demonstrated survival and migration of injected cells in several cochlea regions: vestibular

and tympanic scales, spiral ligament, strias vascularis and modiolo, including spiral ganglion and cochlear nerve (*Naito et al., 2004*).

**Finally**, it is possible that treatments based on the transplant of stem cells may be applied to the damaged inner ear as part of future clinical applications in the treatment of SNHL as the experimental use of stem cells to treat SNHL shows promising results for further clinical application.

## **Aim of the Work**

The aim of this review is to highlight the role of using stem cells in the treatment of SNHL to give us a solid background to carry out an applied research in this field.

# *Acknowledgment*

*I am deeply grateful for the support and constructive guidance of many people, whose valuable assistance made this study possible.*

*First and foremost I would like to express my thanks and deep appreciation to **Prof. Mohamed Magdy Samir**, Professor of otolaryngology and Head & Neck Surgery, Faculty of Medicine-Ain Shams University for encouraging me to develop this subject, and for all inspiring guidance, valuable supervision and help he has given me since I started the research.*

*I am eternally grateful to **Asst. Prof. Mohamed Amir Hassan**, Assistant Professor of otolaryngology and Head & Neck Surgery, Faculty of Medicine-Ain Shams University for his help and keep support, without his help this work would have never been completed. I am deeply indebted to for his scrutiny, his comments and suggestion and his deep interest in the subject.*

*I wish to express my great and ultimate thanks to all my professors and colleagues for their encouragement, help and support.*



*Dedicated to my family and my wife and my  
children Steven and Celina for their*

*Love,*

*Support,*

*Patience*

*And*

*Understanding*

*Michel George Iskander*



# Contents

	<i>Page No.</i>
List of abbreviations .....	i
List of figures .....	3
List of tables .....	3
<b>Introduction</b> .....	<b>E</b>
<b>rror! Bookmark not defined.</b>	
<b>Aim of the Work</b> .....	<b>5</b>
<b>Chapter (1): Physiological Anatomy of Inner Ear</b> .....	<b>6</b>
<b>Chapter (2): Causes of sensineural hearing loss</b> .....	<b>25</b>
<b>Chapter (3): Diagnosis of Sensineural Hearing Loss</b> .....	<b>38</b>
<b>Chapter(4): Concept of Stem Cells</b> .....	<b>47</b>
<b>Chapter(5): Sources of Stem Cells</b> .....	<b>63</b>
<b>Chapter(6): Stem cells &amp; Sensineural Hearing Los</b> .....	<b>73</b>
<b>Discussion</b> .....	<b>105</b>
<b>Recommendations</b> .....	<b>112</b>
<b>Summary</b> .....	<b>128</b>
<b>References</b> .....	<b>113</b>
<b>Arabic Summary</b> .....	<b>—</b>

## **List of Abbreviation**

<b>3NP</b>	: 3-nitropropionic acid
<b>ABR</b>	: Auditory brainstem response.
<b>AD</b>	: Alzheimer's disease.
<b>AIDS</b>	: Acquired immunodeficiency syndrome.
<b>ALS</b>	: Amyotrophic lateral sclerosis.
<b>AP</b>	: Action potential.
<b>BDNF</b>	: Brain-derived neurotrophic factor
<b>bFGF</b>	: Basic fibroblast growth factor
<b>BM</b>	: Basilar Membrane
<b>BMP4</b>	: Bone morphogenetic protein 4
<b>BMT</b>	: Bone marrow transplantation.
<b>CBR</b>	: Cord Blood Registry
<b>CES</b>	: Chronic electrical stimulation
<b>CLW</b>	: Cochlear lateral wall
<b>CM</b>	: Cochlear microphonic.
<b>CN</b>	: Cranial nerve.
<b>CN</b>	: Cranial nerve.
<b>CNS</b>	: Central nervous system.
<b>CPCs</b>	: Circulating progenitor cells.
<b>CT</b>	: Computed tomography.
<b>DPOAE</b>	: Distortion product otoacoustic emission.
<b>DRG</b>	: Dorsal root ganglion neurons
<b>EBs</b>	: Embryoid bodies
<b>EC</b>	: Embryonic carcinoma.
<b>EGF</b>	: Epidermal growth factor
<b>EIM</b>	: Embryonic inner mass.
<b>EPCs</b>	: Endothelial progenitor cells.
<b>ESCs</b>	: Embryonic stem cells.
<b>EYFP</b>	: Enhanced yellow fluorescent protein
<b>FDA</b>	: Food and Drug Administration
<b>FGF</b>	: Fibroblast growth factor
<b>GDNF</b>	: Glial derived neurotrophic factor
<b>HCS</b>	: Hair cells
<b>hEGCs</b>	: Human embryonic germ cells
<b>hESC</b>	: Human embryonic stem cells.
<b>hFASCs</b>	: Human foetal auditory stem

<b>HI</b>	: Hearing Impairment.
<b>HSC</b>	: Hematopoietic stem cell.
<b>IAM</b>	: Internal auditory meatus
<b>ICM</b>	: Inner cell mass.
<b>ICP</b>	: Intracranial pressure.
<b>IGF1</b>	: Insulin-like growth factor 1
<b>IHCs</b>	: Inner hair cells
<b>iPSCs</b>	: Induced pluripotent stem cells
<b>IRBSNHL</b>	: Idiopathic progressive bilateral SNHL
<b>ITSS</b>	: Insulin-transferrin-sodium selenite
<b>LIF</b>	: Leukemia inhibitory factor.
<b>LOC</b>	: Lateral olivocochlear.
<b>LSCC</b>	: Lateral semicircular canal
<b>LSO</b>	: Lateral superior olive.
<b>LVEF</b>	: Left ventricular ejection fraction.
<b>MEFs</b>	: Mouse embryonic fibroblasts
<b>mESC</b>	: Mouse embryonic stem cells.
<b>MOC</b>	: Medial olivocochlear.
<b>MRI</b>	: Magnetic resonance imaging.
<b>MSCs</b>	: Mesenchymal stem cells
<b>MSO</b>	: Medial superior olive.
<b>NGF</b>	: Neurotrophic growth factor
<b>NSAIDS</b>	: Nonsteroidal anti-inflammatory drugs.
<b>NSCs</b>	: Neural stem cells.
<b>NT3</b>	: Neurotrophin-3
<b>OHCs</b>	: Outer hair cells
<b>OSCFM</b>	: Otic stem cell full media
<b>PD</b>	: Parkinson's disease.
<b>RA</b>	: Retinoic acid
<b>RSC</b>	: Retinal stem cell.
<b>SAA</b>	: Severe aplastic anemia.
<b>SCID</b>	: Severe combined immune deficiency.
<b>SDIA</b>	: Stromal-derived inducing activity
<b>SGNs</b>	: Spiral ganglion neurons
<b>SMBs</b>	: Skeletal myoblasts.
<b>SNHL</b>	: Sensorineural hearing loss.
<b>SOC</b>	: Superior olivary complex.
<b>SP</b>	: Summating potential .
<b>SSNHL</b>	: Sudden sensorineural hearing loss.
<b>SVZ</b>	: Subventricular zone.
<b>TM</b>	: Tectorial Membrane .
<b>TOAE</b>	: Transient-evoked otoacoustic emission.

<b>Tuj 1</b>	: Neuron-specific class III beta-tubulin
<b>UCBC</b>	: Umbilical cord blood cells.
<b>VCN</b>	: Ventral cochlear nucleus
<b>VDRL</b>	: Venereal Disease Research Laboratory.
<b>VGLUT</b>	: Vesicular glutamate transporter
<b>WHO</b>	: World Health Organization.
<b>Y-FISH</b>	: Ychromosome fluorescence in situ hybridization

# List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Figure (1):</b>	Inner ear structure.....	8
<b>Figure (2):</b>	The Membranous Labyrinth .....	9
<b>Figure (3):</b>	Diagram of anatomy of cochlea .....	13
<b>Figure (4):</b>	Diagram of Organ of Corti .....	15
<b>Figure (5):</b>	Scanning EM picture of surface of organ of corti.....	18
<b>Figure (6):</b>	Schematic illustrations of (a) midmodiolar section of the guinea pig cochlea and (b) the location of implantation.....	93
<b>Figure (7):</b>	Image illustrating the survival of adult mouse NSCs in the normal guinea pig inner ear 2 weeks following transplantation.....	93
<b>Figure (8):</b>	Postauricular approach to expose the round window of the guinea pig cochlea and inject ES cell types.....	95

## List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Table (1):</b>	Causes of Sensorineural Hearing Loss .....	26
<b>Table (2):</b>	Syndromes with SNHL and associated clinical findings	28
<b>Table (3):</b>	: A classification of congenital malformations of the inner ear	30
<b>Table (4):</b>	WHO grades of hearing impairment .....	40

## **Recommendations**

The advances in stem cell technologies are offering a glimmer of hope for millions of people affected with deafness. Although still at a very early stage, a growing bulk of literature is being produced attempting to pave the path for a stem cell-based therapy for deafness and there are many obstacles must be overcome.

- 1- Specific protocols must be developed to enhance production survival, and integration of transplanted cells.
- 2- More human pluripotent and multipotent cell research is needed since stem cell biology differs in mice and men.
- 3- Finally, clinical trials must be completed to ensure safety and efficacy of the stem cell therapy.